Compare XFOR & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XFOR | LAB |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | 45 | 389 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.7M | 257.2M |
| IPO Year | 2017 | 2008 |
| Metric | XFOR | LAB |
|---|---|---|
| Price | $3.09 | $0.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.60 | N/A |
| AVG Volume (30 Days) | 718.8K | ★ 758.9K |
| Earning Date | 11-04-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | N/A | ★ 0.29 |
| Revenue | $6,500,000.00 | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.26 |
| Revenue Growth | ★ 150.00 | N/A |
| 52 Week Low | $2.43 | $0.59 |
| 52 Week High | $4.83 | $1.72 |
| Indicator | XFOR | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 62.71 |
| Support Level | $2.86 | $0.71 |
| Resistance Level | $4.49 | $0.79 |
| Average True Range (ATR) | 0.25 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 31.09 | 90.33 |
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.